These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

78 related items for PubMed ID: 8857234

  • 1. Factors related to the outcome of M-VAC in 101 patients with advanced urothelial cancer.
    Igawa M, Urakami S, Shirakawa H, Shiina H, Ishibe T, Kadena H, Usui T, Kawanishi M.
    Hiroshima J Med Sci; 1995 Dec; 44(4):113-7. PubMed ID: 8857234
    [Abstract] [Full Text] [Related]

  • 2. [Preliminary results of a phase II randomized controlled trial comparing M-VAC and M-CAVI in patients with bladder cancer (T2-4 N0-1 M0)].
    Bellmunt Molins J, Ribas A, Albanell J, Lorente Garín JA, de Torres Mateos JA, Morote Robles J, López Palacios MA, Banús Gassol JM, Casado Cobo S, Eres N, Solé Calvo LA.
    Arch Esp Urol; 1996 Jun; 49(5):465-72. PubMed ID: 8766083
    [Abstract] [Full Text] [Related]

  • 3. [MEP (methotrexate, etoposide and cisplatin) and M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced uroepithelial cancer--a preliminary report of MEP as second line chemotherapy for recurrence after M-VAC].
    Seguchi T, Nakano E, Miki T, Kondoh M, Nishimura K, Nakamura N, Okuyama A.
    Gan To Kagaku Ryoho; 1994 Jan; 21(1):59-65. PubMed ID: 8291917
    [Abstract] [Full Text] [Related]

  • 4. The effect of cystectomy, and perioperative methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy on the risk and pattern of relapse in patients with muscle invasive bladder cancer.
    Ennis RD, Petrylak DP, Singh P, Bagiella E, O'Toole KM, Benson MC, Olsson CA.
    J Urol; 2000 May; 163(5):1413-8. PubMed ID: 10751847
    [Abstract] [Full Text] [Related]

  • 5. [Chemotherapy of metastatic cancer of the bladder. Apropos of 50 patients treated with M-VAC].
    Beuzeboc P, Dhote R, Thiounn N, Flam T, Zerbib M, Debré B, Pouillart P.
    Cancer Radiother; 1998 Apr; 2 Suppl 1():92s-96s. PubMed ID: 9749087
    [Abstract] [Full Text] [Related]

  • 6. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for poor prognosis patients with urothelial tumors and effect of dose intensity.
    Hibi H, Okamura K, Takashi M, Shimoji T, Miyake K.
    Hinyokika Kiyo; 1997 Feb; 43(2):89-96. PubMed ID: 9086342
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [Combination chemotherapy with M-VAC protocol in metastatic urothelial cancer].
    Sella A, Flex D, Gafni D, Rabinovitz O, Sulkes A, Baniel J.
    Harefuah; 1999 Feb 15; 136(4):268-71, 340, 339. PubMed ID: 10914214
    [Abstract] [Full Text] [Related]

  • 10. [Clinical evaluation of M-VAC (methotrexate, vinblastine, adriamycin and cisplatin) chemotherapy for advanced urothelial cancer].
    Mikami K, Nakagawa S, Takada H, Ebisui K, Sugimoto K, Watanabe H, Maegawa M, Nakao M.
    Hinyokika Kiyo; 1994 Apr 15; 40(4):303-7. PubMed ID: 8191968
    [Abstract] [Full Text] [Related]

  • 11. [Conservative treatment with chemotherapy and radiotherapy in bladder cancer invading the muscle: preliminary results of a prospective study].
    Zapatero A, Pinar B, Arellano R, López M, Marín A, Jiménez U, Pérez Torrubia A.
    Arch Esp Urol; 1997 Jun 15; 50(5):448-54; discussion 454-6. PubMed ID: 9382586
    [Abstract] [Full Text] [Related]

  • 12. Does HER2 immunoreactivity provide prognostic information in locally advanced urothelial carcinoma patients receiving adjuvant M-VEC chemotherapy?
    Tsai YS, Tzai TS, Chow NH.
    Urol Int; 2007 Jun 15; 79(3):210-6. PubMed ID: 17940352
    [Abstract] [Full Text] [Related]

  • 13. [M-VAC chemotherapy for advanced urothelial cancer--side effects and their management].
    Noguchi S, Kubota Y, Shuin T, Masuda M, Misaki H, Yao M, Kondoh K, Sakuramoto T, Hosaka M.
    Hinyokika Kiyo; 1994 Aug 15; 40(8):677-82. PubMed ID: 7942364
    [Abstract] [Full Text] [Related]

  • 14. [Dose intensity in M-VAC chemotherapy with rG-CSF for metastatic transitional urothelial cancer].
    Obata K, Kobayashi H, Takaba H, Yokoi K, Hikosaka A.
    Hinyokika Kiyo; 1994 Oct 15; 40(10):939-44. PubMed ID: 7527613
    [Abstract] [Full Text] [Related]

  • 15. Chemotherapy for advanced urothelial tract tumors: the M-VAC regimen.
    Sternberg CN, Yagoda A, Scher HI.
    Prog Clin Biol Res; 1988 Oct 15; 277():45-51. PubMed ID: 3054909
    [No Abstract] [Full Text] [Related]

  • 16. [Two cases of urothelial cancer responsive to high-dose-intensity methotrexate vinblastine doxorubicin and cisplatin (M-VAC) therapy].
    Fukuda H, Mitsumori K, Minagawa S, Kumazawa T, Tadachi K, Iinuma M, Satoh S, Satoh K, Habuchi T, Kato T.
    Hinyokika Kiyo; 2005 Feb 15; 51(2):113-6. PubMed ID: 15773365
    [Abstract] [Full Text] [Related]

  • 17. [Outcome of treatment with surgical resection of the remaining tumor after modified M-VAC treatment for advanced urothelial carcinoma].
    Narita S, Nakano M, Matsuzaki M, Watanabe J, Morikawa H, Murata H, Oda H, Komatsu H.
    Hinyokika Kiyo; 2005 Mar 15; 51(3):155-8. PubMed ID: 15852667
    [Abstract] [Full Text] [Related]

  • 18. M-VAC (methotrexate, vinblastine, adriamycin and cisplatin) and bladder preservation.
    Scher H, Herr H, Sternberg C, Fair W, Bosl G, Morse M, Sogani P, Watson R, Darshaw D, Reuter V.
    Prog Clin Biol Res; 1990 Mar 15; 353():179-86. PubMed ID: 2217417
    [No Abstract] [Full Text] [Related]

  • 19. Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy.
    George L, Bladou F, Bardou VJ, Gravis G, Tallet A, Alzieu C, Serment G, Salem N.
    Urology; 2004 Sep 15; 64(3):488-93. PubMed ID: 15351577
    [Abstract] [Full Text] [Related]

  • 20. Can patient selection for bladder preservation be based on response to chemotherapy?
    Sternberg CN, Pansadoro V, Calabrò F, Schnetzer S, Giannarelli D, Emiliozzi P, De Paula F, Scarpone P, De Carli P, Pizzo M, Platania A, Amini M.
    Cancer; 2003 Apr 01; 97(7):1644-52. PubMed ID: 12655521
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.